Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Structure Therapeutics Inc. - American Depositary Shares (NQ: GPCR )

30.10 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Structure Therapeutics Inc. - American Depositary Shares

< Previous 1 2 3 4 5 Next >
Why Shares of Structure Therapeutics Are Up Monday
The stock climbed for the second straight day after the company reported positive trial data for its weight-loss therapy drug. 
Via The Motley Fool
Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Shares of Structure Therapeutics Are Soaring on Friday
The company reported positive results from an early-stage clinical trial for its weight-loss therapy candidate. 
Via The Motley Fool
Nasdaq Gains Over 1%; Nike Posts Upbeat Earnings
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining over 1% on Friday. The Dow traded up 0.24% to 33,746.70 while the NASDAQ rose 1.22% to 13,362.51. The S&P 500 also rose,... 
Via Benzinga
Topics Stocks
Exposures US Equities
Newcomer Structure Throws Down The Gauntlet In Obesity Treatment -- Shares Soar 66%
The company is working on a pill to help weight loss, rivaling shots from Novo and, possibly, Lilly. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Is Obesity Focused Structure Therapeutics Stock Trading Higher Today?
Structure Therapeutics Inc (NASDAQ: GPCR) released results from the Phase 1b multiple ascending dose (MAD) study of GSBR-1290 in healthy, overweight, or  
Via Benzinga
Structure Therapeutics Announces $300 Million Private Placement Equity Financing
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
Why Energizer Holdings Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Nuburu, Inc. (NYSE: BURU) shares jumped 185.6% to $1.6593 after the company announced contract with NASA to demonstrate feasibility of power beaming in space using the company’s blue laser... 
Via Benzinga
Fox, Warner Music, Eli Lilly, Chegg And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones falling around 400 points on Tuesday. Here are some big stocks recording gains in today’s session. Paymentus Holdings, Inc. (NYSE: PAY) shares rose 29.4% to... 
Via Benzinga
Structure Therapeutics Appoints Ted W. Love, M.D., to Board of Directors
From Structure Therapeutics Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023
Via Benzinga
The Blazing Weight-Loss Drug Battle: Can Anyone Unseat Undisputed Leaders Novo Nordisk And Lilly?
An overweight world is hungry for new treatments. For now, two companies own the market. 
Via Investor's Business Daily
Why Shares of Structure Therapeutics Rose Monday
The company's lead diabetes and weight-loss therapy may benefit from a decision by Pfizer. 
Via The Motley Fool
Wolfspeed, Genesco, PacWest Bancorp And Other Big Stocks Moving Higher On Monday
U.S. stocks traded mixed, with the Nasdaq Composite gaining around 60 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Cava Stock Makes A Stand In Mixed IPO Landscape: Where Does It Rank Against Other 2023 Wall Street Debuts?
In a year that’s seen a sharp decline in initial public offerings, Washington, D.C.-based Mediterranean restaurant chain Cava Group (NYSE: CAVA) made a striking first public appearance on the New York... 
Via Benzinga
This Biotech Is Developing The Next Ozempic. Should You Buy It?
If it succeeds, it'll still face a battle for market share. 
Via The Motley Fool
Buying Shares of These 2 Biotech Stocks Could Be a Brilliant Move in 5 Years
If you can tolerate the risk and have some patience, both stocks could blossom. 
Via The Motley Fool
Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics to Present at Jefferies Healthcare Conference
From Structure Therapeutics Inc.
Via GlobeNewswire
Booz Allen Hamilton, Workday, Marvell Technology And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining over 300 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Why Hibbett Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Onfolio Holdings, Inc. (NASDAQ: ONFO) gained 73% to $2.02 after the company announced it completed development of a generative AI search tool. 
Via Benzinga
Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Announces Poster Presentations at the American Thoracic Society International Conference
Posters include data across biomarker, translation and clinical studies supporting development of cardiopulmonary programs LTSE-2578 and ANPA-0073 
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
Analysts Sees Over 50% Upside Opportunity For This Newly Listed Obesity Player Stock, Participating In Big Pharma Race
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.